|
1
|
Reuschenbach M, von Knebel, Doeberitz M
and Wentzensen N: A systematic review of humoral immune responses
against tumor antigens. Cancer Immunol Immunother. 58:1535–1544.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan HT, Low J, Lim SG and Chung MC: Serum
autoantibodies as biomarkers for early cancer detection. FEBS J.
276:6880–6904. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kobold S, Lütkens T, Cao Y, Bokemeyer C
and Atanackovic D: Autoantibodies against tumor-related antigens:
incidence and biologic significance. Hum Immunol. 71:643–651. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu W, Peng B, Lu Y, Xu W, Qian W and
Zhang JY: Autoantibodies to tumor-associated antigens as biomarkers
in cancer immunodiagnosis. Autoimmun Rev. 10:331–335. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ludwig N, Keller A, Leidinger P, et al: Is
there a general autoantibody signature for cancer? Eur J Cancer.
48:2451–2461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu YW, Peng YH, Chen B, et al:
Autoantibodies as potential biomarkers for the early detection of
esophageal squamous cell carcinoma. Am J Gastroenterol. 109:36–45.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lam S, Boyle P, Healey GF, et al:
EarlyCDT-Lung: an immunobiomarker test as an aid to early detection
of lung cancer. Cancer Prev Res (Phila). 4:1126–1134. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chapman CJ, Healey GF, Murray A, et al:
EarlyCDT®-Lung test: improved clinical utility through additional
autoantibody assays. Tumour Biol. 33:1319–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jett JR, Peek LJ, Fredericks L, Jewell W,
Pingleton WW and Robertson JF: Audit of the autoantibody test,
Early CDT®-Lung, in 1600 patients: an evaluation of its performance
in routine clinical practice. Lung Cancer. 83:51–55. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chapman C, Murray A, Chakrabarti J, et al:
Autoantibodies in breast cancer: their use as an aid to early
diagnosis. Ann Oncol. 18:868–873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Piura E and Piura B: Autoantibodies to
tailor-made panels of tumor-associated antigens in breast
carcinoma. J Oncol. 2011.9824252011.PubMed/NCBI
|
|
13
|
Hall M, Bates S and Peters G: Evidence for
different modes of action of cyclin-dependent kinase inhibitors:
p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene.
11:1581–1588. 1995.PubMed/NCBI
|
|
14
|
Baldi A, De Luca A, Esposito V, Campioni
M, Spugnini EP and Citro G: Tumor suppressors and cell-cycle
proteins in lung cancer. Pathology Res Int. 2011:6050422011.
View Article : Google Scholar
|
|
15
|
Johnson JL, Pillai S and Chellappan SP:
Genetic and biochemical alterations in non-small cell lung cancer.
Biochem Res Int. 2012:9404052012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsushime H, Ewen ME, Strom DK, et al:
Identification and properties of an atypical catalytic subunit
(p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 71:323–334.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dickson MA: Molecular pathways: CDK4
inhibitors for cancer therapy. Clin Cancer Res. 20:3379–3383. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Looi K, Megliorino R, Shi FD, Peng XX,
Chen Y and Zhang JY: Humoral immune response to p16, a
cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep.
16:1105–1110. 2006.PubMed/NCBI
|
|
19
|
Ye H, Sun C, Ren P, et al: Mini-array of
multiple tumor-associated antigens (TAAs) in the immunodiagnosis of
breast cancer. Oncol Lett. 5:663–668. 2013.PubMed/NCBI
|
|
20
|
Ye L, Guan S, Zhang C, et al: Circulating
autoantibody to FOXP3 may be a potential biomarker for esophageal
squamous cell carcinoma. Tumour Biol. 34:1873–1877. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jin Y, Guan S, Liu L, Sun S, Lee KH and
Wei J: Anti-p16 autoantibodies may be a useful biomarker for early
diagnosis of esophageal cancer. Asian Pac J Clin Oncol. May
9–2014.(Epub ahead of print). View Article : Google Scholar
|
|
22
|
Zhang C, Ye L, Guan S, et al:
Autoantibodies against p16 protein-derived peptides may be a
potential biomarker for non-small cell lung cancer. Tumour Biol.
35:2047–2051. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee CT, Capodieci P, Osman I, et al:
Overexpression of the cyclin-dependent kinase inhibitor p16 is
associated with tumor recurrence in human prostate cancer. Clin
Cancer Res. 5:977–983. 1999.PubMed/NCBI
|
|
24
|
Chen YT, Scanlan MJ, Sahin U, et al: A
testicular antigen aberrantly expressed in human cancers detected
by autologous antibody screening. Proc Natl Acad Sci USA.
94:1914–1918. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanda M, Matthaei H, Wu J, et al: Presence
of somatic mutations in most early-stage pancreatic intraepithelial
neoplasia. Gastroenterology. 142:730–733.e9. 2012. View Article : Google Scholar : PubMed/NCBI
|
